严重的凝血功能障碍和在患有严重功能缺陷的患者中因塞福拉/苏尔巴克坦引起的活跃出血:一个病例报告
Jiayuan Chen1,2, Xia Li3, Xuehui Xiong4
1Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
European journal of hospital pharmacy : science and practice
|April 18, 2025
概括
一种常见的抗生素Cefoperazone/sulbactam可以引起严重的出血和凝血问题,特别是在患有脏问题或营养不良的患者中. 仔细监测和剂量调整至关重要,以防止这些不良药物反应.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 药物不良反应 药物不良反应
背景情况:
- 塞福拉佐/苏尔巴克坦是一种第三代头类药物,经常用于严重感染.
- 凝血病是一种已知的,尽管很少见的,某些抗生素的潜在不良影响.
研究的目的:
- 报告与塞福拉/苏尔巴克坦治疗相关的严重凝血病和出血病例.
- 为了突出监测接受这种抗生素的风险患者的凝血参数的重要性.
主要方法:
- 一份病例报告详细介绍了一名68岁的女性患者,在动脉切割手术后出现出血.
- 使用Naranjo尺度对药物不良反应的评估.
- 对患者停止服用抗生素和服用维生素K1的反应的临床观察.
主要成果:
- 患者在开始服用赛福拉/苏尔巴克坦后出现了严重的凝血功能障碍和活跃出血.
- 停用抗生素和服用维生素K1导致凝血功能正常化.
- 纳兰霍尺度表明,佩拉/苏尔巴克坦与不良事件之间存在可能的因果关系 (得分为6).
结论:
- 塞福拉/苏尔巴克坦可以诱导显著的凝血病,特别是在患有功能衰竭和营养不良等并发症的患者中.
- 密切监测凝血参数和适当的剂量调整对于降低风险至关重要.
- 这一案例强调了临床药剂师在药物管理和跨专业合作中的关键作用.
相关概念视频
Renal Failure: Dose Adjustments
35
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
35
Anticoagulant Drugs: Low-Molecular-Weight Heparins
545
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
545
Disorders of Hemostasis
638
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
638
Factors Affecting Renal Clearance: Renal Impairment
30
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
30
Renal Drug Excretion: Tubular Secretion
88
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
88
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
997
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
997


